A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay

Doghish, Ahmed S.; Ismail, Ahmed; Elrebehy, Mahmoud A.; Elbadry, Abdullah M.M.; Mahmoud, Hend H.; Farouk, Salma M.; Serea, Ghada A. Abu; Elghany, Rahma Ali A.; El-Halwany, Kholoud K.; Alsawah, Abdulrahman Omar; Dewidar, Hla I.; El-Mahdy, Hesham A.

doi:10.1016/j.prp.2022.154053

Cited by 60 publications

(3 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of miRNAs in drug resistance has been implicated in a variety of cancers [77][78][79][80][81][82][83][84][85][86]. By regulating the expression of different downstream targets, miRNAs impact a wide range of biological processes that contribute to therapy resistance [78,[87][88][89][90][91].…”

Section: Hif-related Hypoxia-responsive Non-coding Rnas and Chemother...mentioning

confidence: 99%

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Lee,

Koseki,

Haitani

et al. 2024

Cancers

View full text Add to dashboard Cite

In hypoxic regions of malignant solid tumors, cancer cells acquire resistance to conventional therapies, such as chemotherapy and radiotherapy, causing poor prognosis in patients with cancer. It is widely recognized that some of the key genes behind this are hypoxia-inducible transcription factors, e.g., hypoxia-inducible factor 1 (HIF-1). Since HIF-1 activity is suppressed by two representative 2-oxoglutarate-dependent dioxygenases (2-OGDDs), PHDs (prolyl-4-hydroxylases), and FIH-1 (factor inhibiting hypoxia-inducible factor 1), the inactivation of 2-OGDD has been associated with cancer therapy resistance by the activation of HIF-1. Recent studies have also revealed the importance of hypoxia-responsive mechanisms independent of HIF-1 and its isoforms (collectively, HIFs). In this article, we collate the accumulated knowledge of HIF-1-dependent and independent mechanisms responsible for resistance of hypoxic cancer cells to anticancer drugs and briefly discuss the interplay between hypoxia responses, like EMT and UPR, and chemoresistance. In addition, we introduce a novel HIF-independent mechanism, which is epigenetically mediated by an acetylated histone reader protein, ATAD2, which we recently clarified.

show abstract

Section: Hif-related Hypoxia-responsive Non-coding Rnas and Chemother...mentioning

confidence: 99%

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Lee,

Koseki,

Haitani

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…MiRNAs are small non-coding RNAs that are found in all eukaryotic cells and play a vital role in post-transcriptional inhibition of target mRNAs [ 23 , 24 ]. MiRNAs have pivotal roles in lung tumor progression by regulation of various cellular processes such as cell proliferation, angiogenesis, and epithelial-mesenchymal transition (EMT) [ 25 , 26 ]. They are implicated in drug resistance by affecting various cellular processes such as cell survival, apoptosis, angiogenesis, and migration [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

“…2 ). ROS is implicated in both targeted-therapy resistance and chemical resistance that introduce the redox pathway as a reliable tumor therapeutic target [ 21 – 25 ]. KEAP1 acts as an adaptor for substrates by attaching to the CuI3-containing E3 ubiquitin ligase and destructing them through the proteasome pathway [ 115 ].…”

Section: Introductionmentioning

confidence: 99%

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells

Maharati

Moghbeli

2023

Cell Div

View full text Add to dashboard Cite

Lung cancer as the leading cause of cancer related mortality is always one of the main global health challenges. Despite the recent progresses in therapeutic methods, the mortality rate is still significantly high among lung cancer patients. A wide range of therapeutic methods including chemotherapy, radiotherapy, and surgery are used to treat lung cancer. Doxorubicin (DOX) and Paclitaxel (TXL) are widely used as the first-line chemotherapeutic drugs in lung cancer. However, there is a significant high percentage of DOX/TXL resistance in lung cancer patients, which leads to tumor recurrence and metastasis. Considering, the side effects of these drugs in normal tissues, it is required to clarify the molecular mechanisms of DOX/TXL resistance to introduce the efficient prognostic and therapeutic markers in lung cancer. MicroRNAs (miRNAs) have key roles in regulation of different pathophysiological processes including cell division, apoptosis, migration, and drug resistance. MiRNA deregulations are widely associated with chemo resistance in various cancers. Therefore, considering the importance of miRNAs in chemotherapy response, in the present review, we discussed the role of miRNAs in regulation of DOX/TXL response in lung cancer patients. It has been reported that miRNAs mainly induced DOX/TXL sensitivity in lung tumor cells by the regulation of signaling pathways, autophagy, transcription factors, and apoptosis. This review can be an effective step in introducing miRNAs as the non-invasive prognostic markers to predict DOX/TXL response in lung cancer patients.

show abstract

Nanomedicine Combats Drug Resistance in Lung Cancer

Zheng,

Song,

Zhu

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multi‐functional and tunable physiochemical properties in alignment with tumor genetic profiles could achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, we review the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy and radiotherapy, and outline novel strategies for the development of nanomedicine against drug resistance. We focus on engineering design, customized delivery, current challenges and clinical translation of nanomedicine in the application of resistant lung cancer.This article is protected by copyright. All rights reserved

show abstract

A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay

Cited by 60 publications

References 158 publications

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells

Nanomedicine Combats Drug Resistance in Lung Cancer

Contact Info

Product

Resources

About